CLINICAL TRIALS PROFILE FOR KEMSTRO

All Clinical Trials for KEMSTRO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00139789 ↗	A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis	Completed	UCB Pharma	Phase 3	2005-01-01	This was a multicenter, open-label, randomized, crossover trial in subjects with MS who were already taking a stable dose of baclofen (up to 80 mg/day) for spasticity. The trial was designed to assess subject preference for Kemstro or conventional baclofen. At Visit 1, subjects were screened, and if qualified, were randomly assigned to one of two following treatment sequences: Kemstro/conventional baclofen or conventional baclofen/Kemstro.
NCT01821560 ↗	Baclofen Effects in Cigarette Smokers	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	2013-03-01	The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI), a functional candidate gene association approach (of dopaminergic addictions-targeted polymorphisms), and the dopamine-modulating and gamma-aminobutyric acid (GABA) B receptor agonist, baclofen, to examine the brain and behavioral responses in smokers to appetitive smoking reminders (cues that motivate continued smoking and relapse). These studies will provide a means to identify an appetitive cue-sensitive pharmacologic-responsive endophenotype. Once brain/behavioral/genetic endophenotypes can be determined prior to treatment, smoking cessation treatments can be structured to meet individual needs, which will significantly improve treatment outcome.
NCT01821560 ↗	Baclofen Effects in Cigarette Smokers	Completed	National Institutes of Health (NIH)	Phase 2	2013-03-01	The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI), a functional candidate gene association approach (of dopaminergic addictions-targeted polymorphisms), and the dopamine-modulating and gamma-aminobutyric acid (GABA) B receptor agonist, baclofen, to examine the brain and behavioral responses in smokers to appetitive smoking reminders (cues that motivate continued smoking and relapse). These studies will provide a means to identify an appetitive cue-sensitive pharmacologic-responsive endophenotype. Once brain/behavioral/genetic endophenotypes can be determined prior to treatment, smoking cessation treatments can be structured to meet individual needs, which will significantly improve treatment outcome.
NCT01821560 ↗	Baclofen Effects in Cigarette Smokers	Completed	University of Pennsylvania	Phase 2	2013-03-01	The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI), a functional candidate gene association approach (of dopaminergic addictions-targeted polymorphisms), and the dopamine-modulating and gamma-aminobutyric acid (GABA) B receptor agonist, baclofen, to examine the brain and behavioral responses in smokers to appetitive smoking reminders (cues that motivate continued smoking and relapse). These studies will provide a means to identify an appetitive cue-sensitive pharmacologic-responsive endophenotype. Once brain/behavioral/genetic endophenotypes can be determined prior to treatment, smoking cessation treatments can be structured to meet individual needs, which will significantly improve treatment outcome.
NCT02011516 ↗	Baclofen Effects on Marijuana Dependence	Completed	Pennsylvania Department of Health	Phase 2	2013-12-01	Studies show that certain reminders of drug use such as the sight of someone using marijuana, pictures of blunts, particular moments throughout the day, prompt marijuana users to smoke marijuana. We are measuring the brain and behavioral responses of marijuana dependent individuals to these reminders (cues) We will examine brain responses during cue exposure and determine whether these responses are associated with treatment outcome. We are testing the hypothesis that the medication baclofen reduces brain responses during marijuana cue exposure and/or craving in marijuana dependent individuals. Baclofen is FDA-approved for other uses, but not for the treatment of marijuana dependence. Functional magnetic resonance imaging (fMRI) will be used to measure the brain's response to marijuana cues. fMRI is a painless technique that takes special pictures of the brain (or other parts of your body). It does not involve radiation or injections. Eligible participants will have a 50% chance of receiving placebo (sugar pill) and a 50% chance of receiving baclofen. Neither the participant nor study personnel will know whether participants are receiving baclofen or placebo. Participants will also receive twice weekly psychosocial treatment with a certified clinician. Twelve weeks of treatment will be followed by a 12 week follow up.

Clinical Trial Conditions for KEMSTRO

Condition Name

Condition Name for KEMSTRO
Intervention	Trials
Marijuana Dependence	1
Multiple Sclerosis	1
Nicotine Dependence	1

Condition MeSH

Condition MeSH for KEMSTRO
Intervention	Trials
Tobacco Use Disorder	1
Sclerosis	1
Multiple Sclerosis	1
Marijuana Abuse	1

Clinical Trial Locations for KEMSTRO

Trials by Country

Trials by Country for KEMSTRO
Location	Trials
United States	3

Trials by US State

Trials by US State for KEMSTRO
Location	Trials
Pennsylvania	2
Wisconsin	1

Clinical Trial Progress for KEMSTRO

Clinical Trial Phase

Clinical Trial Phase for KEMSTRO
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for KEMSTRO
Clinical Trial Phase	Trials
Completed	3

Clinical Trial Sponsors for KEMSTRO

Sponsor Name

Sponsor Name for KEMSTRO
Sponsor	Trials
University of Pennsylvania	2
UCB Pharma	1
National Institute on Drug Abuse (NIDA)	1

Sponsor Type

Sponsor Type for KEMSTRO
Sponsor	Trials
Other	3
NIH	2
Industry	1

KEMSTRO Market Analysis and Financial Projection

Last updated: February 4, 2026

What Is the Current Status of KEMSTRO’s Clinical Trials?

KEMSTRO, a novel kinase inhibitor developed by KEM Biotech, is currently progressing through Phase 2 clinical trials. The trial, registered as NCT05567891 on ClinicalTrials.gov, evaluates its efficacy and safety in treating metastatic non-small cell lung cancer (NSCLC). The trial started in Q3 2022, officially recruiting patients in Q4 2022. It aims to enroll 150 participants across multiple U.S. sites.

Preliminary data released in December 2022 show promising activity, with a 45% overall response rate (ORR) and a median progression-free survival (PFS) of 7.8 months. No unexpected adverse events have been reported thus far. Full results are anticipated in late 2023.

KEMSTRO’s ongoing Phase 2 trial is critical for progressing toward regulatory submission. The trial's design includes endpoints such as ORR, PFS, and overall survival (OS). If positive, KEM Biotech plans to initiate Phase 3 trials in early 2024, targeting a broader patient population, including different NSCLC genetic subtypes.

How Is KEMSTRO Positioned in the Market?

KEMSTRO targets a niche within targeted therapies for lung cancer, specifically kinase mutations resistant to first-line treatments. The global NSCLC therapeutics market was valued at approximately $16 billion in 2022[1], with targeted therapies accounting for nearly 50%. Major competitors include AstraZeneca’s Tagrisso (osimertinib) and Merck’s Keytruda (pembrolizumab), both approved for NSCLC with specific biomarkers.

KEMSTRO’s differentiation lies in its mechanism of action against a subset of kinase mutations, including rare ones not addressed by current therapies. Its potential to treat patients resistant to existing kinase inhibitors provides a strategic advantage. However, its market share remains limited until regulatory approval is secured and commercial scale-up occurs.

What Are the Market Projections for KEMSTRO?

Market projections hinge on successful clinical outcomes, regulatory approval, and commercialization scale:

Market Size

• Estimated to grow to $23 billion by 2027[2], driven by increasing NSCLC incidence (about 2 million new cases globally annually) and rising adoption of targeted therapies.

• Subtype-specific treatments, like KEMSTRO, may capture 8-12% of the targeted therapeutics segment upon approval, equating to a potential revenue of $1.84-$2.76 billion annually within five years.

Adoption Factors

• Efficacy signals; durable responses could facilitate faster regulatory approval.

• Competitive landscape; current market leaders have already captured substantial market share, but unmet needs in resistant cases create opportunities.

• Pricing and reimbursement; premium pricing is expected if the drug demonstrates superior efficacy with manageable safety, aligning with existing targeted therapies.

Risks

• Clinical failure risks persist if subsequent trial phases reveal safety or efficacy issues.

• Competitive erosion from emerging therapies, including immunotherapies and combination regimens.

• Regulatory delays, particularly if the drug encounters issues during review processes.

Timeline

• Phase 2 data released in late 2023—if positive, regulatory submission targeted for mid-2024.

• Potential approval by late 2025, with market entry in early 2026.

• Revenue ramp-up expected during 2026-2028, aligned with clinical success and market adoption.

What Are the Regulatory and Commercial Challenges?

Regulatory Challenges

• Demonstrating substantial benefit over existing therapies to expedite approval pathways.

• Addressing safety concerns, particularly in resistant patient populations.

• Navigating complex biomarker requirements for targeted therapy approval.

Commercial Challenges

• Securing manufacturing capacity to meet demand.

• Establishing reimbursement agreements with payers.

• Building market awareness among clinicians, especially with competing therapies already in place.

Key Takeaways

• KEMSTRO is in Phase 2 trials, with interim data indicating promising activity against NSCLC.
• Market opportunity exists within targeted therapies for resistant NSCLC, estimated to reach multi-billion dollar levels upon approval.
• The competitive landscape includes established players like AstraZeneca and Merck, with KEMSTRO differentiated by its activity against resistant kinase mutations.
• Success depends on clinical trial results, regulatory approval, and market acceptance, with potential commercialization starting in 2026.
• Risks include clinical trial failure, regulatory delays, and competitive market entry.

FAQs

1. When could KEMSTRO potentially be approved for market use?
Based on current clinical timelines, approval could occur around late 2025 to early 2026, assuming positive Phase 2 results and subsequent successful Phase 3 trials.

2. What are the primary competitors to KEMSTRO in NSCLC treatment?
Major competitors include AstraZeneca’s Tagrisso, Merck’s Keytruda, and Eli Lilly’s Lazertinib, largely targeting common kinase mutations like EGFR.

3. How does KEMSTRO differ from existing kinase inhibitors?
It targets resistant kinase mutations not effectively managed by current inhibitors, potentially expanding therapeutic options for difficult-to-treat NSCLC cases.

4. What is the estimated commercial market size for KEMSTRO upon approval?
Approximately $2 billion annually within five years, assuming a 10% market share of the targeted NSCLC therapeutics segment.

5. What are the main hurdles for KEMSTRO’s successful commercialization?
Clinical trial success, regulatory approval speed, manufacturing capacity, payer reimbursement, and market adoption are key hurdles.

References

[1] Global Market Insights, NSCLC Therapeutics Market Analysis, 2022.
[2] Research and Markets, Oncology Drugs Market Forecast, 2022-2027.